IPP Bureau
Merck’s KEYTRUDA combo wins key EU backing for bladder cancer treatment
By IPP Bureau - May 25, 2026
The decision now moves to the European Commission, with a final ruling expected by the third quarter of 2026
Datroway wins US nod in aggressive breast cancer subtype
By IPP Bureau - May 25, 2026
Clearance marks major shift beyond chemotherapy
Oral GLP-1 race heats up as Lilly’s Foundayo shines in seniors
By IPP Bureau - May 25, 2026
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
AbbVie scores key EU backing for Hepatitis C drug in push for earlier treatment
By IPP Bureau - May 25, 2026
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
WHO declares Ebola outbreak, Indians advised against travel to affected regions
By IPP Bureau - May 25, 2026
No approved vaccine or specific treatment currently available for Bundibugyo strain Ebola disease
Anupam Rasayan to acquire 43.3%–48.2% equity stake in Bliss GVS Pharma
By IPP Bureau - May 25, 2026
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
SMS Pharma posts 48% profit surge in FY26 as margins expand & portfolio shift drives growth
By IPP Bureau - May 25, 2026
Revenue from operations climbed 13% to Rs. 886.87 crore
Akumentis Healthcare appoints Dharnendra Doshi as Senior Vice President
By IPP Bureau - May 25, 2026
Veteran consumer health and FMCG strategist to lead preventive wellness and nutrition portfolio expansion through innovation and modern trade channels
AstraZeneca breast cancer drug wins key EU backing after cutting progression risk by 56%
By IPP Bureau - May 25, 2026
The recommendation is powered by blockbuster results from the pivotal Phase III SERENA-6 trial
Zota Health Care posts 83.86% revenue surge in FY26
By IPP Bureau - May 25, 2026
Expands Davaindia network to 2,579 stores
EMA accepts filing for Teva and Medincell’s long-acting schizophrenia treatment candidate
By IPP Bureau - May 25, 2026
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
EU regulator backs Allergan Aesthetics’ Boey in key step toward approval
By IPP Bureau - May 25, 2026
The decision marks a key step in the centralized EU review process
Lilly brings heavy oncology firepower to ASCO with plenary data across cancers
By IPP Bureau - May 25, 2026
The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy
Bristol Myers Squibb to unveil massive oncology data push at ASCO 2026
By IPP Bureau - May 25, 2026
The company said the breadth of its showcase reflects “progress from its differentiated oncology pipeline in solid tumors and hematologic malignancies,”
AbbVie signals major oncology momentum at ASCO
By IPP Bureau - May 25, 2026
With standout ADC and t-cell engager response data across hard-to-treat cancers
